In a patient with hypertension currently taking carvedilol 25 mg twice daily and isosorbide mononitrate 30 mg daily, who cannot use lisinopril because of hyperkalemia and has an amlodipine allergy, and whose blood pressure remains elevated, what is the next best medication to add?

Next Best Antihypertensive Agent

Add chlorthalidone 12.5–25 mg once daily as your next agent. This patient requires a thiazide-like diuretic to achieve blood pressure control, and chlorthalidone is the preferred choice over hydrochlorothiazide based on its superior efficacy and cardiovascular outcomes data.

Rationale for Thiazide-Like Diuretic Selection

The patient is currently on carvedilol (a beta-blocker) and isosorbide (a nitrate vasodilator), neither of which represents optimal first-line hypertension therapy according to current guidelines. 1, 2 The patient cannot use:

• ACE inhibitors (lisinopril caused hyperkalemia) 1
• Calcium channel blockers (amlodipine allergy) 2
• ARBs (would carry similar hyperkalemia risk as ACE inhibitors in this patient) 1, 2

This leaves thiazide-like diuretics as the most appropriate next step from the first-line antihypertensive classes. 1, 3

Why Chlorthalidone Over Hydrochlorothiazide

Chlorthalidone is strongly preferred because it offers:

• Prolonged half-life providing 24-hour blood pressure control 1
• Proven reduction in cardiovascular disease in major outcome trials 1, 4
• Greater antihypertensive efficacy than hydrochlorothiazide at equivalent doses 5
• Dosing of 12.5–25 mg once daily is effective and minimizes adverse effects 1, 4

The ACC/AHA guidelines explicitly state that "chlorthalidone is preferred on the basis of prolonged half-life and proven trial reduction of CVD." 1

Addressing the Current Regimen

Carvedilol Considerations

The patient is already on carvedilol 25 mg twice daily, which is at the maximum recommended dose for hypertension. 6 While beta-blockers are not preferred as first-line agents for uncomplicated hypertension, 1, 7, 5 carvedilol should be continued if there are compelling indications such as:

• Heart failure with reduced ejection fraction 8, 3
• Post-myocardial infarction 8, 6
• Coronary artery disease 8

If no compelling indication exists, consider whether carvedilol is truly necessary, as it may be contributing to inadequate blood pressure control compared to other first-line agents. 1, 5

Isosorbide Concerns

Isosorbide mononitrate 30 mg daily is not a standard antihypertensive agent and is typically used for angina management. 8 It can cause:

• Peripheral edema (especially in elderly patients) 9
• Orthostatic hypotension when combined with other blood pressure medications 6
• Tolerance with continuous use, reducing efficacy

Verify the indication for isosorbide—if it's being used solely for blood pressure control, this is inappropriate and should be reconsidered. 8

Implementation Strategy

Starting Chlorthalidone

• Initial dose: 12.5 mg once daily 1, 5
• Titration: Increase to 25 mg once daily after 7–14 days if blood pressure remains elevated and the lower dose is tolerated 1, 4
• Maximum dose: Do not exceed 25 mg daily, as higher doses increase adverse effects without significant additional benefit 4
• Timing: Take in the morning to avoid nocturia 1

Monitoring Requirements

Within 1 month of starting chlorthalidone, check: 7

• Serum potassium (watch for hypokalemia, though this patient's baseline hyperkalemia may actually improve) 1, 10
• Serum sodium (monitor for hyponatremia) 1
• Renal function (serum creatinine/eGFR) 7
• Uric acid (use with caution if history of gout) 1
• Calcium levels 1

Blood Pressure Targets

• Goal: <130/80 mmHg for most adults 11, 3, 5
• Timeline: Achieve target within 3 months 11, 3
• Follow-up: Reassess blood pressure every 2–4 weeks during titration 5

Alternative Considerations if Chlorthalidone Fails

If blood pressure remains uncontrolled after optimizing chlorthalidone (and assuming carvedilol is continued for a compelling indication), the next step would be: 12, 3

Step 4 therapy: Add spironolactone 25 mg once daily if serum potassium <4.6 mmol/L. 12, 3, 5 However, given this patient's history of hyperkalemia with lisinopril, spironolactone carries significant risk and would require:

• Very close monitoring of potassium (within 1 month, then regularly) 12, 7
• Consideration of alternative agents such as doxazosin, clonidine, or hydralazine if spironolactone is contraindicated 12, 11, 3

Common Pitfalls to Avoid

1. Do not use hydrochlorothiazide instead of chlorthalidone without good reason—chlorthalidone is superior. 1, 5

2. Do not add an ARB thinking it will avoid the hyperkalemia seen with lisinopril—ARBs carry the same hyperkalemia risk as ACE inhibitors. 1, 2, 10

3. Do not combine ACE inhibitors and ARBs—this is explicitly contraindicated and increases adverse events without benefit. 1, 3, 5

4. Monitor for orthostatic hypotension given the combination of carvedilol, isosorbide, and now a diuretic—all can contribute to postural blood pressure drops. 6, 9

5. Ensure adequate sodium restriction (<2400 mg/day) to maximize diuretic efficacy. 12

6. Verify medication adherence before escalating therapy—use home blood pressure monitoring or 24-hour ambulatory monitoring to exclude white-coat hypertension. 12, 11